key: cord-0885810-86fkfbh0
authors: nan
title: 肿瘤患者新冠疫苗接种：临床研究进展与初步临床推荐
date: 2021-06-20
journal: Zhongguo Fei Ai Za Zhi
DOI: 10.3779/j.issn.1009-3419.2021.101.18
sha: 2c64ae8b5b1aa3fdc510819bf839cbe0bd735bb9
doc_id: 885810
cord_uid: 86fkfbh0

The pandemic of coronavirus disease 2019 (COVID-19) has had a serious impact on global health. COVID-19 vaccines may be one of the most effective measure to end the pandemic. High infection risk and higher serious incident and mortality rates have been shown in cancer patients with COVID-19. Therefore, cancer patients should be the priority group for COVID-19 prevention. Until now, data of COVID-19 vaccination for cancer patients is lacking. We review the interim data of safety and immune-efficacy of COVID-19 vaccination in cancer patients based on the latest studies. Due to the complicated immune systems of cancer patients caused by the malignancy and anticancer treatments, we proposed preliminary specific COVID-19 vaccination recommendations for cancer patients with different anticancer treatments and at different stages of the disease. Preventing COVID-19 with vaccinations for cancer patients is crucial, and we call for more large-scale clinical trials and real-world studies, for further COVID-19 vaccination recommendations development.

、癌症免疫治 疗学会 [9] 、法国免疫治疗协会 [10] 

COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

The ESMO call to action on COV ID-19 vaccinations and patients with cancer: Vaccinate. monitor. educate

Society for Immunotherapy of Cancer. SITC statement on SA RS-CoV-2 vaccination and cancer immunotherapy. SIT Cancer

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)

Epidemiology Working Group for Ncip Epidemic Response CCf DC, Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Food and Drug Administration. FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine

Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: The PROFISCOV study

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of the

Ch AdOx1 nCoV-19 vaccine (AZD1222) against SA RS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Efficacy and safety of the mR NA-1273 SA R S-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

SARS-CoV-2 vaccines for cancer patients: a call to action

Safety and immunogenicity of one versus two doses of the COV ID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv

Cell-mediated immunogenicity of inf luenza vaccination in patients with cancer receiving immune checkpoint inhibitors

Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update

Inf luenza vaccines in immunosuppressed adults with cancer

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated www.lungca.org with immune checkpoint inhibitors

Immune-mediated adverse events following influenza vaccine in cancer patients receiving immune checkpoint inhibitors

Safety of inactivated inf luenza vaccine in cancer patients receiving immune checkpoint inhibitors

Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey

Vaccine enthusiasm and hesitancy in cancer patients and the impact of a webinar

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

T hrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Thrombotic thrombocytopenia af ter Ad26.COV2 .S vaccination

Response to inf luenza virus vaccination during chemotherapy in patients with breast cancer

Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours

COVID-19 Vaccination for Cancer Patients: Progress and Preliminary Recommendations